08:00 , Dec 20, 2012 |  BC Innovations  |  Strategy

MRC Technology extends reach

After six years of focusing on developing small molecule drug candidates and humanizing therapeutic mAbs, both mostly from U.K. source, MRC Technology , the commercialization arm of the country's Medical Research Council , is taking...
07:00 , Oct 3, 2011 |  BC Week In Review  |  Clinical News

AP214: Phase IIb data

Top-line data from a double-blind, U.S. and Danish Phase IIb trial in 77 patients undergoing cardiac surgery with cardiopulmonary bypass showed that AP214 met the primary endpoint of achieving significantly lower creatinine levels at day...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

AP214: Phase IIb started

Action Pharma began a double-blind, placebo-controlled, U.S. and Danish Phase IIb trial to evaluate 2 doses of AP214 given 3 times as a bolus injection in 75 patients undergoing cardiac surgery under cardiopulmonary bypass. Action...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche 's Genentech Inc. unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease. 1 Nineteen of the 112 candidate...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Clinical News

AP214: Interim Phase II data

Interim data from a double-blind, placebo-controlled, Danish Phase II trial in 42 patients showed that 10, 50 and 200 µg/kg doses of IV AP214 were well tolerated. At the highest dose, AP214 prevented increases in...
07:00 , May 31, 2010 |  BioCentury  |  Finance

Performance Counts

BioCentury's eighth annual review of the financing needs for European biotech shows a record number of biopharma companies have reached the clinic and beyond. While in total these private and public biotechs also have registered...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

AP214: Phase II completed

Action Pharma completed enrollment and dosing of 42 patients in a double-blind, placebo-controlled, Danish Phase II trial evaluating intravenous AP214. The company licensed worldwide rights to develop and commercialize AP214 from Zealand Pharma in 2003....
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

AP214: Phase II started

Action Pharma began a double-blind, placebo-controlled, Danish Phase II trial to evaluate intravenous AP214 in 42 patients undergoing cardiac surgery. The company licensed worldwide rights to develop and commercialize the product from Zealand in 2003....
07:00 , Jun 30, 2008 |  BC Week In Review  |  Clinical News

AP214: Phase II started

Action began a double-blind, placebo-controlled, U.S. Phase II trial of intravenous AP214 in about 75 patients. Action Pharma A/S , Holte, Denmark   Product: AP214   Business: Renal   Molecular target: Melanocortin 1 receptor (MC1R)...
07:00 , Aug 28, 2000 |  BC Week In Review  |  Company News

Merck Research Laboratories other research news

Merck researchers published in Nature Genetics that mice lacking the Mc3r gene have two-fold increased fat mass, 15-20 percent reduced lean mass and a higher ratio of weight gain to food intake despite eating less...